273 related articles for article (PubMed ID: 30489651)
1. Long-term improvement in cardiac magnetic resonance in β-thalassemia major patients treated with deferasirox extends to patients with abnormal baseline cardiac function.
Casale M; Filosa A; Ragozzino A; Amendola G; Roberti D; Tartaglione I; De Michele E; Cozzolino D; Rispoli G; Palmieri F; Pugliese U; Scianguetta S; Signoriello G; Musallam KM; Perrotta S
Am J Hematol; 2019 Mar; 94(3):312-318. PubMed ID: 30489651
[TBL] [Abstract][Full Text] [Related]
2. Five Years of Deferasirox Therapy for Cardiac Iron in β-Thalassemia Major.
Vlachaki E; Agapidou A; Spanos G; Klonizakis P; Vetsiou E; Mavroudi M; Boura P
Hemoglobin; 2015; 39(5):299-304. PubMed ID: 26177199
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of deferasirox for reducing total body and cardiac iron in thalassemia.
Merchant R; Ahmed J; Krishnan P; Jankharia B
Indian Pediatr; 2012 Apr; 49(4):281-5. PubMed ID: 21992861
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal prospective comparison of pancreatic iron by magnetic resonance in thalassemia patients transfusion-dependent since early childhood treated with combination deferiprone-desferrioxamine vs deferiprone or deferasirox monotherapy.
Ricchi P; Meloni A; Pistoia L; Gamberini MR; Cuccia L; Allò M; Putti MC; Spasiano A; Rosso R; Cecinati V; Righi R; Renne S; Peritore G; Vallone A; Positano V; Quaia E; Cademartiri F; Pepe A
Blood Transfus; 2024 Jan; 22(1):75-85. PubMed ID: 37146300
[TBL] [Abstract][Full Text] [Related]
5. Long-term chelation therapy with deferasirox: effects on cardiac iron overload measured by T2* MRI.
Ruffo GB; Borsellino Z; Cuccia L; Marocco MR; Gagliardotto F; Tarantino R
Clin Drug Investig; 2010; 30(4):267-73. PubMed ID: 20225910
[TBL] [Abstract][Full Text] [Related]
6. [Curative effects and safety of deferasirox in treatment of iron overload in children with β-thalassemia major].
Gao HY; Li Q; Chen JJ; Chen GF; Li CG
Zhongguo Dang Dai Er Ke Za Zhi; 2011 Jul; 13(7):531-4. PubMed ID: 21752315
[TBL] [Abstract][Full Text] [Related]
7. Modern management of iron overload in thalassemia major patients guided by MRI techniques: real-world data from a long-term cohort study.
Bayraktaroglu S; Karadas N; Onen S; Karapinar DY; Aydinok Y
Ann Hematol; 2022 Mar; 101(3):521-529. PubMed ID: 34985558
[TBL] [Abstract][Full Text] [Related]
8. Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major.
Pennell DJ; Porter JB; Cappellini MD; Chan LL; El-Beshlawy A; Aydinok Y; Ibrahim H; Li CK; Viprakasit V; Elalfy MS; Kattamis A; Smith G; Habr D; Domokos G; Roubert B; Taher A
Haematologica; 2012 Jun; 97(6):842-8. PubMed ID: 22271905
[TBL] [Abstract][Full Text] [Related]
9. Comparative Efficacy and Safety Between Deferiprone and Deferasirox with Special Reference to Serum Ferritin Level and Cardiac Function in Bengali β-Thalassemia Major Children.
Tripathy I; Panja A; Dolai TK; Mallick AK
Hemoglobin; 2021 Sep; 45(5):296-302. PubMed ID: 34758688
[TBL] [Abstract][Full Text] [Related]
10. One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation.
Inati A; Kahale M; Sbeiti N; Cappellini MD; Taher AT; Koussa S; Nasr TA; Musallam KM; Abbas HA; Porter JB
Pediatr Blood Cancer; 2017 Jan; 64(1):188-196. PubMed ID: 27576370
[TBL] [Abstract][Full Text] [Related]
11. A 5-year follow-up in deferasirox treatment: improvement of cardiac and hepatic iron overload and amelioration in cardiac function in thalassemia major patients.
Cassinerio E; Roghi A; Orofino N; Pedrotti P; Zanaboni L; Poggiali E; Giuditta M; Consonni D; Cappellini MD
Ann Hematol; 2015 Jun; 94(6):939-45. PubMed ID: 25563596
[TBL] [Abstract][Full Text] [Related]
12. MRI multicentre prospective survey in thalassaemia major patients treated with deferasirox versus deferiprone and desferrioxamine.
Pepe A; Meloni A; Pistoia L; Cuccia L; Gamberini MR; Lisi R; D'Ascola DG; Rosso R; Allò M; Spasiano A; Restaino G; Righi R; Mangione M; Positano V; Ricchi P
Br J Haematol; 2018 Dec; 183(5):783-795. PubMed ID: 30334574
[TBL] [Abstract][Full Text] [Related]
13. Effect of deferasirox on iron overload in patients with transfusion-dependent haemoglobinopathies.
Fragomeno C; Roccabruna E; D'Ascola DG
Blood Cells Mol Dis; 2015 Dec; 55(4):382-6. PubMed ID: 26460263
[TBL] [Abstract][Full Text] [Related]
14. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
Daar S; Pathare AV
Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
[TBL] [Abstract][Full Text] [Related]
15. The long-term efficacy and tolerability of oral deferasirox for patients with transfusion-dependent β-thalassemia in Taiwan.
Chang HH; Lu MY; Peng SS; Yang YL; Lin DT; Jou ST; Lin KH
Ann Hematol; 2015 Dec; 94(12):1945-52. PubMed ID: 26404899
[TBL] [Abstract][Full Text] [Related]
16. Role of vitamin C as an adjuvant therapy to different iron chelators in young β-thalassemia major patients: efficacy and safety in relation to tissue iron overload.
Elalfy MS; Saber MM; Adly AA; Ismail EA; Tarif M; Ibrahim F; Elalfy OM
Eur J Haematol; 2016 Mar; 96(3):318-26. PubMed ID: 26018112
[TBL] [Abstract][Full Text] [Related]
17. Tolerability and efficacy of deferasirox in patients with transfusional iron overload: results from a German 2-year non-interventional study.
Nolte F; Nückel H; Schmidt B; Geer T; Rubanov O; Hebart H; Jarisch A; Albrecht S; Johr C; Schumann C; Hofmann WK
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1531-1538. PubMed ID: 29761371
[TBL] [Abstract][Full Text] [Related]
18. Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload.
Pennell DJ; Porter JB; Cappellini MD; Chan LL; El-Beshlawy A; Aydinok Y; Ibrahim H; Li CK; Viprakasit V; Elalfy MS; Kattamis A; Smith G; Habr D; Domokos G; Roubert B; Taher A
Haematologica; 2011 Jan; 96(1):48-54. PubMed ID: 21071497
[TBL] [Abstract][Full Text] [Related]
19. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
Cassinerio E; Orofino N; Roghi A; Duca L; Poggiali E; Fraquelli M; Zanaboni L; Cappellini MD
Blood Cells Mol Dis; 2014 Sep; 53(3):164-7. PubMed ID: 24846580
[TBL] [Abstract][Full Text] [Related]
20. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
Totadri S; Bansal D; Bhatia P; Attri SV; Trehan A; Marwaha RK
Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
